Skip to main content
Premium Trial:

Request an Annual Quote

SIRS-Lab, Pfizer Target Sepsis with MDx Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm SIRS-Lab today announced a collaboration with Pfizer Pharma focused on sepsis diagnostics and treatment.

The firms will initially evaluate the clinical impact of using molecular-based tests for diagnosis of severe fungal blood stream infections, as well as the pharmacoeconomics of such an approach.

Financial and other terms of the deal were not disclosed.

Each year, more than 2 million people in Europe and North America are affected by sepsis, a leading cause of death in hospitals. In a statement, SIRS-Lab said that patients with sepsis may not be receiving proper treatment, as evidence of antibiotic resistance mounts. With molecular diagnostic tests, a microbe can be identified in a few hours, leading to quicker tailoring of the treatment.

Based in Jena, Germany, SIRS-Lab develops and commercializes products for the diagnosis and monitoring of life-threatening infections. It has developed a proprietary sample preparation technology called Looxster, used within the company's Vyoo CE-marked sepsis test. Another test being planned for launch, Siqnature, monitors the body's immune response to infection through gene expression.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.